Literature DB >> 16469812

Role of the alternate pathway of dihydrotestosterone formation in virilization of the Wolffian ducts of the tammar wallaby, Macropus eugenii.

Geoffrey Shaw1, Jane Fenelon, Michelle Sichlau, Richard J Auchus, Jean D Wilson, Marilyn B Renfree.   

Abstract

Dihydrotestosterone in androgen target tissues is formed under most circumstances by the 5alpha-reduction of testosterone, but an alternate pathway involves the oxidation of androstanediol to dihydrotestosterone. To investigate the mechanism by which androgens virilize the Wolffian ducts in the tammar wallaby, [(3)H]progesterone was incubated with testes from d 10 and 19 pouch young, and radioactivity was recovered in testosterone and androstanediol at both ages. Analysis of the intermediates indicates that androstanediol was formed both from testosterone via 5alpha-reduction and 3alpha-keto reduction and directly from 5alpha-reduced progestogens. 5alpha-Reductase activity was high in minces of mesonephros/epididymis from d 6-21 pouch young. When minces of urogenital tract tissues from d 19 pouch young were incubated with [(3)H]testosterone, [(3)H]dihydrotestosterone, and [(3)H]androstanediol, dihydrotestosterone was the principal androgen formed in the mesonephros/epididymis, urogenital sinus, and urogenital tubercle, whereas androstanediol was the principal androgen formed by the testis. In intact pouch young studied between d 10 and 34, administration of the 5alpha-reductase inhibitor, 17beta-(N,N-diethyl)carbamoyl-4-methyl-4-aza-5alpha-androstan-3-one, blocked virilization of the Wolffian ducts in males, and administration of androstanediol caused virilization of the Wolffian ducts in females. We conclude that dihydrotestosterone, largely formed in the tissue by the oxidation of androstanediol derived from the testes and also the 5alpha-reduction of testosterone, is responsible for Wolffian duct virilization in this species.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16469812     DOI: 10.1210/en.2005-1251

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  12 in total

1.  Lucky, times ten: A career in Texas science.

Authors:  David W Russell
Journal:  J Biol Chem       Date:  2018-12-07       Impact factor: 5.157

2.  Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.

Authors:  James L Mohler; Mark A Titus; Elizabeth M Wilson
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

3.  Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial.

Authors:  Shalender Bhasin; Thomas G Travison; Thomas W Storer; Kishore Lakshman; Manas Kaushik; Norman A Mazer; Ahn-Hoa Ngyuen; Maithili N Davda; Hernan Jara; Adam Aakil; Stephan Anderson; Philip E Knapp; Samson Hanka; Nurahmed Mohammed; Pierre Daou; Renee Miciek; Jagadish Ulloor; Anqi Zhang; Brad Brooks; Katie Orwoll; Leife Hede-Brierley; Richard Eder; Ayan Elmi; Geeta Bhasin; Lauren Collins; Ravinder Singh; Shehzad Basaria
Journal:  JAMA       Date:  2012-03-07       Impact factor: 56.272

4.  Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.

Authors:  James L Mohler; Mark A Titus; Suxia Bai; Brian J Kennerley; Fred B Lih; Kenneth B Tomer; Elizabeth M Wilson
Journal:  Cancer Res       Date:  2011-02-08       Impact factor: 12.701

Review 5.  The opossum genome: insights and opportunities from an alternative mammal.

Authors:  Paul B Samollow
Journal:  Genome Res       Date:  2008-08       Impact factor: 9.043

Review 6.  The adrenal cortex and sexual differentiation during early human development.

Authors:  Daniel J Asby; Wiebke Arlt; Neil A Hanley
Journal:  Rev Endocr Metab Disord       Date:  2009-03       Impact factor: 6.514

Review 7.  Androgen biosynthesis in castration-resistant prostate cancer.

Authors:  Trevor M Penning
Journal:  Endocr Relat Cancer       Date:  2014-05-14       Impact factor: 5.678

Review 8.  Gonadal steroid hormones and the hypothalamo-pituitary-adrenal axis.

Authors:  Robert J Handa; Michael J Weiser
Journal:  Front Neuroendocrinol       Date:  2013-11-16       Impact factor: 8.606

Review 9.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

10.  Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer.

Authors:  Fumio Ishizaki; Tsutomu Nishiyama; Takashi Kawasaki; Yoshimichi Miyashiro; Noboru Hara; Itsuhiro Takizawa; Makoto Naito; Kota Takahashi
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.